BIO in the news: Drug, biotech industries weigh election's impact

11/3/2004 | USA Today · MarketWatch · Kentucky.com

The outcome of the presidential election sent pharmaceutical and biotechnology stocks rising, but at least one analyst said the "enthusiasm could be short-lived" because the issues that faced the industries before the election still remain. But others see President George W. Bush's re-election as making it less likely the government will impose price controls. Scientists anticipate conflict between individual states and the federal government over a variety of issues during Bush's second term. Carl Feldbaum, president of the Biotechnology Industry Organization, argues "the big issues for biotech are who the new president will appoint to key positions such as the FDA commissioner and other agencies if vacancies occur."

View Full Article in:

USA Today · MarketWatch · Kentucky.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC